Brand Name
Somatuline
Generic Name
Lanreotide Acetate
View Brand Information FDA approval date: November 14, 2007
Classification: Somatostatin Analog
Form: Injection
What is Somatuline (Lanreotide Acetate)?
Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment